Asthma Clinical Trial
To improve asthma outcomes by developing and evaluating strategies for enhancing the clinic-patient partnership. To develop a model of shared decision-making for asthma treatment, and to evaluate it in a two-year randomized clinical trial in 342 adults aged 18-70 years with sub-optimally controlled persistent asthma.
BACKGROUND:
Although much is now known about asthma, and there is effective asthma treatment, only about
half of the patients with persistent asthma adhere to their prescribed long-term controller
medication. One way to change this might be to involve patients more in decisions about
their treatment.
DESIGN NARRATIVE:
Overview and study design This study is designed to evaluate the effectiveness of a model of
shared decision-making in improving outcomes in adults aged 18-70 years with suboptimally
controlled, mild-moderate persistent asthma. The shared decision-making model (SD) is being
compared in a randomized controlled trial with a model based on national asthma guidelines
(MG), and with usual care (UC).
Initially, we adapted the model of shared decision-making that has been used successfully in
cancer to make it appropriate for a chronic disease (asthma). We will also adapted the KP
Asthma Guidelines so that the two models (Management by Guidelines and Shared
Decision-Making) take a similar amount of clinician-patient interaction time. We are
comparing the two models and usual care in the primary care setting at Kaiser Permanente
Northwest and Kaiser Permanente Hawaii in a randomized controlled trial with 24-month follow
up. The individual asthma patient will be the unit of randomization.
Interventions were done by a care manager (nurse practitioner or clinical pharmacist) with
experience in asthma, and the authority to change medication regimens. Different staff were
used for the two intervention groups to minimize contamination between the groups
attributable to the intervention. Eligible participants were randomized into the three
groups (UC, MG, and SD) on an equal 1:1:1 basis, stratifying on prior health care
utilization and within center (KPNW or KPH). All study participants are being followed for
24 months with clinic visits for data collection at 12 months. The MG and SD arms are
receiving interim phone calls from the care managers at three, six, and nine months to
assess problems with their treatment regimens, discuss changes that may be desired in
treatment regimens, and encourage adherence. Different staff are responsible for data
collection and intervention.
We will compare the MG and SD models versus usual care (UC vs MG; UC vs SD), and the MG and
SD models (MG vs SD).
The study completion date listed in this record was obtained from the "End Date" entered in
the Protocol Registration and Results System (PRS) record.
;
Allocation: Randomized, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
| Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
| Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
| Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
| Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
| Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
| Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
| Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
| Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
| Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
| Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
| Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
| Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
| Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
| Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
| Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
| Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
| Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
| Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|